Top Abstract Purchase Related
Home
>
Node
>
Subnode

Determination of benzbromarone in serum following combined therapy with allopurinol and benzbromarone

Nitsche, V.; Mascher, H.

Arzneimittel-Forschung 31(3): 510-512

1981

ISSN/ISBN: 0004-4172
PMID: 7194674
Document Number: 181878
A rapid method is described for benzbromarone assay in human serum. Protein precipitation is followed by extraction of the active substance. After centrifugation the clear organic layer is evaporated to dryness, redissolved in methanol and injected on a HPLC-column. Detection limits for this method of assay are 0.1 microgram benzbromarone/ml serum. The blood level for therapeutic concentrations lies between 1 and 2.5 microgram/ml. Some pharmacokinetic data were presented. The half-life of benzbromarone is 2.6 h.

Document emailed within 1 workday
Secure & encrypted payments

Akkasilpa, S.; Osiri, M.; Deesomchok, U.; Avihingsanon, Y. 2004: The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia Journal of the Medical Association of Thailand 87(9): 1087-1091
Matzkies, F. 1983: Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone Fortschritte der Medizin 101(20): 953-959
Walter-Sack, I.; de Vries, J.X.; von Bubnoff, A.; Pfleilschifter, V.; Raedsch, R. 1995: Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites? European Journal of Medical Research 1(1): 16-20
Mertz, D.P. 1978: The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies Münchener Medizinische Wochenschrift 120(42): 1387-1390
Mertz, D.P. 1977: Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances Medizinische Klinik 72(15): 664-668
Ohno, I.; Okabe, H.; Yamaguchi, Y.; Saikawa, H.; Uetake, D.; Hikita, M.; Gomi, H.; Ichida, K.; Hosoya, T. 2008: Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol Nihon Jinzo Gakkai Shi 50(4): 506-512
Matzkies, F. 1979: Behavior of serum and urine sodium and potassium during treatment with benzbromarone Fortschritte der Medizin 97(3): 123-124
Schräpler, P.; Kleinschmidt, A.; Haese, E. 1978: The effect of benzbromarone on fasting-hyperuricemia as a model Medizinische Klinik 73(23): 861-866
Gao, H. 2019: Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia Pakistan Journal of Pharmaceutical Sciences 32(4 Supplary): 1869-1871
Dalbeth, N.; Gow, P.; Stamp, L.; Merriman, T.; Stuart, R.; Winnard, D.; Lindsay, K. 2013: New urate-lowering therapies in Aotearoa New Zealand: a response to Dr Lance Gravatt's letter on benzbromarone hepatotoxicity New Zealand Medical Journal 126(1382): 120-123
Zazgornik, J.; Hruby, K.; Schmidt, P.; Kopsa, H.; Pils, P. 1979: Hemolysis after combined azathioprine and allopurinol therapy Acta Medica Austriaca 6(5): 197-199
Schuster, O.; Haertel, M.; Hugemann, B.; Gikalov, I.; Schiemann, O.; Fenner, H. 1985: The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability Arzneimittel-Forschung 35(4): 760-765
Rootwelt, K. 1971: Thyroxine iodine in the blood. Evaluation of the diagnostic possibilities of serum thyroxine determined by competitive radioimmunoassay, along with serum thyroxine determination combined with the triiodothyronine test and estimation of the free thyroxine factor Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 91(21): 1534-1538
Hahn, H.K.; Williams, R.V.; Burch, R.E.; Sullivan, J.F.; Novak, E.A. 1972: Determination of serum selenium by means of solvent extraction combined with activation analysis Journal of Laboratory and Clinical Medicine 80(5): 718-722
Shturkalev, I.; Kiutukchiev, B.; Skrinska, E.; Vlasova, D.; Stanislavov, R. 1976: Quantitative determination of serum proteins in the cervical mucus following the use of a combined contraceptive preparation Akusherstvo i Ginekologiia 15(2): 89-94
Liu, C.F.; Jiao, K.; Pan, X.Q.; Zhao, W.C. 1989: Determination of allopurinol in tablets and urine by oscillopolarography Yao Xue Xue Bao 24(9): 690-696
Follath, F.; Roth, M.; Wenk, M.; Peyer, H.; Fridrich, R. 1977: Determination of serum digoxin: a path to better control of therapy? Schweizerische Medizinische Wochenschrift 107(44): 1561-1563
Xu, K.C.; Wei, Q.; Meng, X.Y. 1987: Diagnostic significance of the combined determination of serum alpha-1-antitrypsin and alpha-1-antichymotrypsin for primary hepatocellular carcinoma Zhonghua Nei Ke Za Zhi 26(1): 27-29; 63
Hinkel, G.K.; Schwarze, R.; Kintzel, H.W. 1972: The influence of combined therapy with orotic acid and phenobarbital on the level of serum bilirubin in premature infants Schweizerische Medizinische Wochenschrift 102(10): 331-335
Cserhalmi, L. 1998: Effect of combined captopril-spironolactone therapy of cardiac insufficiency on kidney function and serum electrolyte values Orvosi Hetilap 139(2): 63-66